Related by context. All words. (Click for frequent words.) 66 CTRC AACR San Antonio 66 AACR San Antonio 65 Therapeutics TCT scientific 65 Gastrointestinal Cancers Symposium 65 Medical Oncology ESMO 65 CLARITY TIMI 64 Hematology ASH Annual Meeting 64 European CanCer Organisation ECCO 63 Genitourinary Cancers Symposium 63 Gastrointestinal Cancer 63 ASCO GI 63 AASLD Meeting 63 SABCS 63 TG MV 63 annual Transcatheter Cardiovascular 62 Hematology Annual Meeting 62 #nd EORTC NCI 62 Clinical Oncology Annual Meeting 62 Annual Scientific Sessions 61 Randomized Phase 61 Phase III AFFIRM 61 Annual Transcatheter Cardiovascular 61 ASH Annual Meeting 61 Transcatheter Cardiovascular Therapeutics TCT 61 Rheumatology ACR Annual 61 ExTRACT TIMI 61 Connective Tissue Oncology 61 ORAL Sync 61 EULAR Annual 60 SPIRIT IV 60 Chicago Multidisciplinary Symposium 60 ECTRIMS 60 UEGW 60 Randomized Phase II 60 Therapeutics TCT 60 Hsp# Inhibitor 60 Clinical Trial Results 60 AACR #st Annual Meeting 60 RECORD1 60 comparing alemtuzumab 60 Gynecologic Oncology Group 60 Cardiostim 60 Preclinical Study 59 EORTC NCI AACR 59 AUA Annual Meeting 59 Cancers Symposium 59 EORTC NCI AACR Symposium 59 fosbretabulin 59 Transcatheter Cardiovascular Therapeutics 59 Combination REOLYSIN R 59 Phase #b/#a clinical 59 CALGB 59 Carotid Revascularization Endarterectomy vs. 59 League Against Rheumatism 59 Late Breaker 59 Hematology Meeting 59 EVEREST II 59 Endovascular Valve Edge 59 PROactive Study 59 Intervention Effectiveness 59 SUCCEED trial 59 Chronic Lymphocytic Leukemia CLL 59 Aflibercept 59 Symposium SABCS 59 II Clinical Trial 58 EURIDIS 58 evaluating tivozanib 58 AACR symposium 58 Tanespimycin 58 Related Disorders ICAD 58 Pooled Analysis 58 ongoing Phase 1b 58 Prostate AdenoCarcinoma Treatment 58 ERA EDTA 58 PERSEUS clinical program 58 EORTC NCI 58 AVERROES 58 Phase 2b Clinical Trial 58 Delcath Phase III 58 Breast Cancer Symposium SABCS 58 Infectious Diseases ECCMID 58 PreCISe 58 INSPIRE Trial Phase III 58 registrational Phase 58 bazedoxifene conjugated estrogens 58 randomized Phase III 58 ENDEAVOR III 58 FOLOTYN ® 58 BOLDER II 58 Pivotal Clinical Trial 58 ROCKET AF 58 Society CTOS 58 BARI 2D 58 Digestive Disease Week DDW 58 Oral Fingolimod 57 ENDEAVOR IV 57 Malignant Lymphoma 57 Deforolimus 57 Breast Cancer Symposium 57 AACR #nd Annual Meeting 57 Stenting Trial CREST 57 Randomized Phase III 57 Randomized Double blind 57 fidaxomicin Phase 3 57 Daclizumab 57 #th Annual Interscience 57 Biological Therapy 57 EuroPCR 57 sorafenib tablets 57 Kahalalide F 57 ASCO Annual Meeting 57 ECCO ESMO 57 Edge STudy 57 CARE HF 57 #rd Annual CTRC 57 BiTE R 57 Ovarian PLCO Cancer 57 #nd Annual Meeting 57 HORIZONS AMI 57 Double Blind Placebo 57 worsening thrombocytopenia 57 BRIM3 57 trastuzumab DM1 T DM1 57 Phase III placebo controlled 57 ENESTnd 57 dose escalation clinical 57 ThermoDox ® clinical 57 Acute Myocardial Infarction 57 KRN# 57 nd Annual Meeting 57 Selective Cardiac Myosin 56 ONTARGET 56 randomized controlled Phase 56 Completes Patient Enrollment 56 #th Interscience Conference 56 Digital Mammographic Imaging 56 Clinical Microbiology 56 Asthma Intervention 56 huC# DM4 56 Preclinical Data 56 Clinical Antipsychotic Trials 56 Hedgehog Pathway Inhibitor 56 Clinical Oncology ASCO Annual 56 Hematological Malignancies 56 Pivotal Trial 56 IL# PE#QQR 56 plus Copegus R 56 HCV RESPOND 2 56 PERSEUS 56 ToGA 56 Rheumatology Annual 56 Metastatic Melanoma 56 ICAAC IDSA 56 ASBMR 56 FOLFOX6 chemotherapy regimen 56 Val HeFT 56 Opportunistic Infections CROI 56 SPIRIT FIRST 56 Temsirolimus 56 BR.# 56 AACR Symposium 56 Pirfenidone 56 evaluating mipomersen 56 Annual Interscience Conference 56 ASCO Breast Cancer 56 Breaking Clinical Trials 56 Nordic ACTI 56 Endocrine Society Annual Meeting 56 multicenter randomized controlled 56 Overactive Bladder OAB 56 TAXUS ATLAS 56 ORAL Solo 56 lexidronam injection 56 BCIRG 56 Therapeutic Radiation 56 metastatic castration resistant 56 Digestive Diseases Week 56 Intervention Effectiveness CATIE 56 PROSTVAC TM 56 Arch Surg 56 Chemotherapy ICAAC 56 multicenter Phase 56 CLL8 55 AACR IASLC Joint 55 Scientific Sessions 55 ADVANCE PD 55 Neuro Oncology SNO 55 assessing T DM1 55 Brentuximab Vedotin SGN 55 AACR Meeting 55 Aggressive Reduction 55 Phase Ib clinical trials 55 oral dual endothelin 55 sunitinib Sutent 55 stent DES 55 IMPACT IMmunotherapy 55 Tesetaxel 55 Arteriosclerosis Thrombosis 55 st Annual Meeting 55 VEITHsymposium 55 Clinical Oncology Gastrointestinal Cancers 55 number NCT# ClinicalTrials.gov 55 HFSA Annual 55 MEND CABG 55 ARVO 55 Clinical Trials Update 55 axitinib 55 USpella 55 Liver EASL 55 RE LY 55 Female Urology 55 Abstract Accepted 55 PROSTASCINT R 55 NEVO RES 55 BRIM2 55 Gastroenterology ACG Annual 55 multicenter multinational 55 placebo controlled clinical 55 ZYBRESTAT fosbretabulin 55 Molecular Targets 55 Association EHA 55 AVADO 55 Urology EAU 55 Sipuleucel T 55 Meets Primary Endpoint 55 Safinamide 55 Randomized Clinical Trial 55 Controlled Trial 55 EchoCRT 55 Celecoxib APC trial 55 Digestive Disease Week 55 Prolongs Survival 55 Folfox 55 antibody blinatumomab MT#/MEDI-# 55 Carotid Endarterectomy 55 Screening Trial 55 Endovascular Therapy 55 Acute Ischemic Stroke 55 ABCSG 55 Diabetic Macular Edema 55 Platelet Inhibition 55 pan HDAC inhibitor 55 Cloretazine ® 55 AACR NCI EORTC 55 phase IIb clinical 55 HCV SPRINT 55 ADA Scientific Sessions 55 recurrent GBM 55 YONDELIS 55 Annual ICAAC 55 RIO Lipids 55 neratinib 55 PROVENGE sipuleucel T 55 Gemzar ® 54 Phase Ib II 54 PFO migraine 54 ACR ARHP 54 Phase 2a clinical 54 Bucindolol 54 Prospective Multicenter 54 Chemotherapy ICAAC Infectious Diseases 54 Hypertension ASH 54 histone deacetylase HDAC inhibitor 54 Hematology ASH Meeting 54 SCAI Annual 54 ECCMID 54 ASTRO Annual Meeting 54 phase IIa clinical 54 novel VDA molecule 54 America HFSA 54 Haemostasis ISTH 54 phase IIa 54 multicenter placebo controlled 54 Glucosamine Chondroitin Arthritis 54 standard chemotherapy regimen 54 Vascular Annual Meeting 54 ECASS 54 MT# MEDI 54 Stent Thrombosis 54 multicenter clinical 54 pralatrexate injection folate analogue 54 Carfilzomib 54 Prostate Lung Colorectal 54 Phase Ib study 54 cediranib 54 NO# [002] 54 Developmental Therapeutics Immunotherapy 54 perifosine KRX 54 Zenvia Phase III 54 Pediatric Oncology Branch 54 Radiation Oncology ASTRO 54 chemotherapy gemcitabine 54 Endourology 54 Chronic Lymphocytic Leukemia 54 Endovascular Therapy ISET 54 ACR ARHP Annual 54 Phase Ib clinical 54 Endocrine Society ENDO 54 Endeavor Drug Eluting 54 HORIZONS AMI trial 54 ARBITER 6 54 CAMMS# 54 preclinical efficacy 54 substudy 54 mGluR5 negative 54 CLARITY study 54 Lung Transplantation 54 Initiated Phase 54 AHA Scientific Sessions 54 coronary stent merged 54 SAR# [004] 54 Phase III ALLEGRO 54 Multicenter 54 Proc Am Soc 54 Phase 2a Clinical Trial 54 MGd 54 ESMO 54 orally inhaled migraine 54 Postmenopausal Women 54 ASCO Gastrointestinal Cancers Symposium 54 Neurology Annual Meeting 54 ASTEROID 54 Teplizumab 54 TASKi2 54 EXPAREL ™ 54 Phase III psoriasis 54 evaluating REVLIMID 54 hormone refractory metastatic prostate 54 randomized controlled clinical 54 International Verapamil SR 54 CUSTOM III 54 CALGB # [002] 54 Immunomedics Announces 54 Multiple Sclerosis ECTRIMS 53 Endocrine Society #st 53 Oligonucleotide Therapeutics Society 53 Advanced Renal Cell 53 recurrent malignant glioma 53 Personalized Immunotherapy 53 Prostate Cancer Symposium 53 DASISION 53 International Myeloma Workshop 53 HCV NS5B polymerase 53 sulodexide 53 Cardiomyocytes 53 AACR Frontiers 53 EFNS 53 NASDAQ CXSP announced 53 Lenocta 53 Movement Disorder 53 Glufosfamide 53 Ocrelizumab 53 randomized discontinuation trial 53 TAXUS Element Paclitaxel Eluting 53 HDAC Inhibitor 53 ASCO GU 53 ICAAC 53 First Patient Enrolled 53 CTRC AACR 53 LUX Lung 53 ISPOR 53 Refractory Angina 53 undergoing elective percutaneous 53 ASGT 53 Hodgkin lymphoma HL 53 pertuzumab 53 prospective multicenter randomized 53 Hormone Refractory Prostate Cancer 53 Lipid Lowering Treatment 53 Deutsches Herzzentrum 53 Neurology AAN 53 NASDAQ CYTK announced 53 Breaking Clinical Trial 53 Group RTOG 53 AAO HNSF Annual Meeting 53 Gene Therapy ASGT 53 trastuzumab emtansine T DM1 53 Retina Specialists 53 trial evaluating PRX# 53 Long Term Efficacy 53 Cardiac Techniques 53 EOquin TM phase 53 vascular disrupting agent 53 BioNumerik 53 ASCO Genitourinary Cancers Symposium 53 sorafenib Nexavar 53 metastatic HRPC 53 GENASIS 53 GVAX ® 53 Anti Tumor Activity 53 Cardiology ESC Congress 53 #st Annual Meeting 53 CIMZIA TM certolizumab pegol 53 catheter occlusion 53 viral kinetic 53 Lancet Oncology journal 53 Cancer Immunotherapy 53 Eluting Coronary Stent System 53 recurrent glioblastoma multiforme 53 HDL Selective Delipidation 53 Elagolix 53 Belimumab 53 Amrubicin 53 AIR2 Trial 53 Poster Discussion 53 Ophthalmology ARVO 53 Epeius Biotechnologies Corporation 53 Scientific Session 53 statistically significant efficacy 53 pharmacokinetic PK study 53 APPRAISE 53 R roscovitine 53 teriflunomide 53 CTAP# Capsules 53 MERLIN TIMI 53 Cardiovascular Interventions 52 Nasdaq SGMO announced 52 rALLy clinical trial 52 Nephrology Renal Week 52 randomized Phase IIb 52 ® DDW 52 REALITY Trial 52 paclitaxel cisplatin 52 TACI Ig 52 Antitumor Activity 52 alvespimycin 52 EORTC 52 elotuzumab 52 Intervention Trial GAIT 52 Prostate Cancer Prevention 52 Canaccord Adams Hepatitis C 52 Cardiology Heart Failure 52 Demonstrates Sustained 52 BiTE antibody MT# 52 ACRIN 52 CHARISMA trial 52 Selective Cardiac Myosin Activator 52 huN# DM1 52 Solid Tumors 52 oral rivaroxaban 52 GASTRO 52 Thoraxcenter Erasmus University 52 Well Tolerated 52 JAK Inhibitor 52 Pemetrexed 52 BRAF inhibitor 52 ularitide 52 Antiepileptic Drugs 52 ICON7 52 INCB# [001] 52 Oral Presentations 52 multicenter Phase II 52 Neuvenge 52 Phase III VISTA 52 R lenalidomide 52 phase IIIb 52 CROI 52 BIOCOM Investor Conference 52 Anticancer Drug 52 Phase 1b trial 52 enzastaurin 52 RE MODEL 52 Nymox NX 52 SPIRIT III 52 Gastrointestinal Oncology 52 NEUVENGE 52 relapsing remitting MS RRMS 52 Hematology ASH 52 HeFT 52 Outpatient Setting 52 Solorel TM 52 Randomized Study 52 ASCEND HF 52 Microplasmin 52 Neurological Surgeons Annual Meeting 52 mitogen activated ERK kinase 52 ASCO abstract 52 XL# XL# XL# 52 Cardiology Scientific Sessions 52 non nucleoside inhibitor 52 Neuroendocrinology 52 Interventional Therapies 52 EFORT Congress 52 Vaccine Adjuvant 52 Traficet EN 52 Trial PCPT 52 Screening Trial DMIST 52 retinal vein occlusion induced 52 anti arrhythmic drug 52 ADAGIO 52 vismodegib 52 oral FTY# 52 ELACYT 52 journal Lancet Neurology 52 VESTASYNC 52 SYMMETRY trial 52 Targeted Anticancer Therapies 52 Retrovirus Conference 52 Cardiovascular Disease Epidemiology 52 Ceflatonin R 52 Evaluation WISE 52 Radiation Therapy Oncology 52 Minimally Invasive Gynecology 52 satraplatin Phase 52 J Am Coll 52 Safety Tolerability 52 Active Biotech NASDAQ OMX 52 PNP inhibitor 52 PEG SN# 52 ADMIRE HF 52 ISTH 52 Phase III ADT 52 Vandetanib 52 HER2 positive metastatic breast 52 tasocitinib 52 Clinical Oncology ASCO Gastrointestinal 52 Romiplostim 52 FDA Oncologic Drugs 52 Microbiology ASM 52 MEK inhibitor 52 riociguat 52 th Interscience Conference 52 Talabostat 52 YONDELIS R 52 Gastroenterology Week UEGW 52 Diabetes EASD 52 Inc. NASDAQ HEPH 52 AA Amyloidosis 51 RNAi Therapeutic 51 Bortezomib 51 CTI Nasdaq 51 Presents Preclinical Data 51 Novel Oral 51 J Clin Oncol 51 abstracts summarizing 51 Meta Analysis 51 Cell Biology ASCB 51 PARTNER Trial 51 Therapeutic Radiology 51 ACUITY trial 51 Quinamed 51 Cardiac Resynchronization Therapy 51 Antimicrobial Agents 51 Cardiac Resynchronization 51 Respiratory Society 51 CYPHER R Sirolimus Eluting 51 JAK2 Inhibitor 51 Therapeutic Radiation Oncology 51 ZACTIMA 51 journal Gynecologic Oncology 51 Acute Heart Failure 51 MERIT ES 51 preclinical pharmacokinetic 51 CT Colonography Trial 51 prospective observational 51 Ocular Pharmacology 51 Dose Escalation 51 Sangamo BioSciences Announces 51 J Clin Endocrinol Metab 51 IMPROVE HF 51 Breast Surgeons ASBS 51 TORISEL TM 51 Antifungals 51 Pharmacokinetic 51 Nexavar sorafenib 51 Inflammatory Arthritis 51 Pre RELAX AHF 51 Aplidin R 51 CYT# potent vascular disrupting 51 Clinical Virology Symposium 51 Relapsing Multiple Sclerosis 51 novel histone deacetylase 51 PSMA ADC 51 Cardiovascular Therapeutics 51 SU# [003] 51 Denufosol 51 ThermoDox R 51 AACR Annual Meeting 51 Gynecologic Investigation 51 ZD# [001] 51 ATACAND 51 Tolvaptan 51 Cancer iSBTc 51 Clinical Trial Data 51 oncolytic virus therapies 51 Gynecologic Cancer Society 51 Phase 2a trial 51 Announces Poster Presentations 51 American Roentgen Ray 51 Ranolazine 51 Ambrisentan 51 phase IIb trial 51 Castration Resistant Prostate Cancer 51 metastatic colorectal 51 depsipeptide 51 Controlled Release 51 acute PAO 51 subgroup analyzes 51 NASDAQ SLXP today 51 Endocrine Society #nd 51 MADIT CRT 51 PKC# 51 Phase 2a Trial 51 essential thrombocythemia ET 51 transthyretin TTR mediated amyloidosis 51 Ixempra 51 LymphoStat B TM 51 candesartan cilexetil 51 galiximab 51 Interscience Conference 51 Cancer Therapeutic 51 AAN Annual Meeting 51 RE LY trial 51 Molecular Origins 51 Acute Decompensated Heart Failure 51 RCW Breast Cancer 51 NCIC CTG 51 RGB # 51 Epileptology 51 Liver Diseases AASLD 51 Neurological Societies 51 PANVAC VF 51 oral prodrug 51 Myelodysplastic Syndromes 51 prostate cancer mCRPC 51 paclitaxel eluting stents 51 sunitinib malate 51 ZOLINZA 51 Phase Ib Clinical Trial 51 NCCTG 51 Phase IIB 51 relapsed refractory multiple myeloma 51 Carla Vecchiotti 51 Allergology 51 BZA CE 51 COU AA 51 trastuzumab DM1 51 CombAT 51 Nicotine Vaccine 51 Abstract Number 51 Pediatric Academic Societies PAS 51 Phase 2a Study 51 Aggressive Drug Evaluation 51 HGS# 51 Xcytrin R 51 Spine Arthroplasty Society 51 Paroxysmal Nocturnal Hemoglobinuria PNH 51 recurrent glioma 51 National Surgical Adjuvant 51 ALN TTR 51 Clinical Efficacy 51 Omacetaxine 51 Endoscopic Surgeons 51 MT#/MEDI-# 51 HCV Protease Inhibitor 51 CURRENT OASIS 7 51 ixabepilone 51 Anti Tumor 51 Poster Presentations 51 NCCTG N# 51 Gastric Cancer 51 Nephrology Annual Meeting 51 ganetespib 50 investigational immunotherapy 50 phase IIb study 50 DG# compounds targeting 50 Recurrent Chest Wall 50 adecatumumab 50 PROactive study 50 dual endothelin receptor antagonist 50 LibiGel Phase III 50 Aplidin 50 ALN VSP 50 Dr. Pingpank 50 Genasense ® 50 Venereology EADV 50 HDL Mimetic Peptide 50 ARVO Annual Meeting 50 Oncology ASTRO 50 phase IIb 50 Hematological 50 Nasdaq SNSS 50 GW# [003] 50 Therapeutic Targets 50 relapsed multiple myeloma 50 Hematology Molecular Pathology 50 Radiology Imaging Network ACRIN 50 Murdo Maguire 50 Kinase Inhibitor 50 Vulnerable Plaque 50 Stem Cell Research ISSCR 50 pharmacokinetic PK 50 PRECISE 50 Reverset 50 Heart Failure Society 50 Oncology ESTRO 50 Faslodex 50 ECNP Congress 50 trabectedin 50 LymphoStat B 50 Immunology Annual Meeting 50 Preclinical Models 50 REG2 50 Oak Brook Ill. RSNA.org 50 Clinical Oncology JCO 50 Biological Effects 50 SWOG 50 NSABP 50 CAPRISA 50 Randomized controlled 50 Enzastaurin 50 metaglidasen 50 Nephrology CJASN 50 Dr. Gulfo 50 Presents Preclinical 50 TAXUS IV 50 Aneurysm Repair 50 forodesine 50 Bazedoxifene 50 PEGylated interferon beta 1a 50 oral proteasome inhibitor 50 International Neuropsychological Society 50 Dialysis Outcomes 50 CR# vcMMAE 50 MYTHOS trial 50 Artificial Organs 50 Phase IIB clinical 50 BiTE ® 50 Tumor Microenvironment 50 AAG geldanamycin analog 50 mg administered orally 50 fidaxomicin Phase 50 randomized multicenter trial 50 cetuximab Erbitux 50 Nasdaq IDRA today 50 anticancer compound 50 PRIMO CABG2 50 Anticancer Drugs 50 Clinical Oncology ASCO 50 varespladib 50 Femara letrozole 50 Retroviruses 50 Mineral Research ASBMR 50 HCV polymerase inhibitors 50 ENMD # 50 including eniluracil ADH 50 Clin Chem 50 orally administered inhibitor 50 VADT 50 Bipolar Disorders 50 metastatic renal cell carcinoma 50 brivaracetam 50 Diabet Med 50 Opportunistic Infections 50 TTF Therapy 50 ESTRO 50 Perifosine 50 INGN 50 Physiological Chemistry 50 QLT# 50 CoFactor 50 visit www.dobimedical.com 50 midstage clinical 50 resistant hormone refractory 50 journal Gene Therapy 50 Cardiology ESC 50 PCI ExTRACT TIMI 50 Naurex 50 Interventional Radiology SIR 50 iniparib 50 targeting CD# 50 Dendritic Cells 50 meta analysis pooling 50 Breast Surgeons 50 Vascular Biology ATVB 50 Azedra 50 entitled Synergistic 50 HIF PHI 50 Cell Transplant 50 Aryplase 50 Boceprevir 50 Doxil ® 50 Antiviral Activity 50 Oral Presentation 50 CYPHER R Sirolimus eluting 50 Cardiovascular Anesthesiologists 50 Sym# 50 Unither 50 Targeted Therapies 50 Heart Failure Patients 50 Preclinical Efficacy 50 EMBO J. 50 Annual BIO 50 ASN Renal Week 50 Elvitegravir 50 Poster Presentation 50 Ann Oncol 50 ® cetuximab 50 Cardiology ACC 50 Tumor Response 50 Reolysin 50 Sequenced Treatment Alternatives 50 Percutaneous Cardiovascular Interventions 50 Cardiol 50 EASL 50 Fondaparinux 49 investigational antiplatelet 49 rALLy trial 49 CUSTOM II 49 ST Elevation Myocardial 49 Certican 49 Zarnestra 49 HuMax EGFr 49 Lancet Neurology journal 49 International OARSI 49 Phase III ThermoDox 49 metastatic CRC 49 GRNCM1 49 CRLX# 49 GTCbio 49 Antibody Therapeutics 49 Cholesterol Levels SPARCL 49 resolvin 49 CBLC# 49 DDW ® 49 ACC.# 49 Podium Presentation 49 INTERHEART study 49 Gleevec imatinib mesylate 49 oral ridaforolimus 49 vinca alkaloid 49 Rheumatology Annual Meeting 49 Monoclonal Antibodies 49 Endocrine Practice 49 phase 2a 49 Dacogen injection 49 phase Ib 49 Am J Epidemiol 49 Interventions SCAI 49 Innate Immunity 49 EDEMA3 trial 49 unresectable liver cancer 49 Inc. Nasdaq AVRX 49 bevacizumab Avastin 49 iPrEx 49 J Natl Cancer Inst 49 ASGCT 49 proteasome inhibitor 49 Minimally Invasive Spine Surgery 49 rosuvastatin #mg 49 Lysosomal Disease Network 49 Rheumatology EULAR 49 Gynecologic Oncologists 49 Liver Meeting 49 HepaSphere 49 mRCC 49 EnteroMedics proprietary neuroblocking technology 49 iSBTc 49 OXi# 49 OMP #M# 49 ILLUMINATE 49 Systemic Delivery 49 Onrigin 49 decitabine 49 Thrombolytic Therapy 49 www.nejm.org 49 Hypertension ESH 49 Inflammatory Bowel Diseases 49 conradm 49 SPARCL 49 seliciclib CYC# 49 Xelox 49 ANN INTERN MED 49 NASDAQ PCYC 49 Molecular Medicine Tri 49 PERISCOPE 49 www.asco.org 49 ASMS Conference 49 European CanCer Organisation 49 resistant ovarian cancer 49 Pharmaceutical Scientists AAPS 49 Valsartan 49 Needham Biotechnology 49 & OTO EXPO 49 Dasatinib 49 pain palliation 49 Applied Spectroscopy 49 Romidepsin 49 gefitinib Iressa 49 EGS# 49 Thoracic Oncology 49 Antiviral Research 49 Genta Incorporated OTCBB GETA 49 PROTECT II 49 aflibercept 49 radezolid 49 HGS ETR1 49 PLCO 49 mCRC 49 Pazopanib 49 SA FC# 49 AEG# 49 Venous Thromboembolism 49 Subgroup analysis 49 San Antonio Breast Cancer 49 Frankfurt XMP 49 atypical Hemolytic Uremic Syndrome 49 thetreatment 49 Multiethnic Study 49 Ann Rheum Dis 49 Dr. Ayalew Tefferi 49 tolvaptan 49 selective kinase inhibitor 49 Phase #/#a trial 49 Pluristem Therapeutics 49 Guidelines Recommend 49 Diabetologia 49 Molecular Cancer 49 OncoVEX GM CSF 49 CIMZIA ™ 49 IRX 2 49 Randomized Controlled Trials 49 Hepatocellular Carcinoma HCC 49 Phase III Trials 49 SCCHN 49 Phase Ib 49 Neuropsychopharmacology ECNP 49 rivaroxaban Xarelto 49 vidofludimus 49 Cell Lung Cancer 49 Bioral ® 49 Survival Benefit 49 Randomized Comparison 49 entinostat 49 Candesartan 49 subanalysis 49 Phase #/#a 49 olaparib 49 Kaplan Meier analysis 49 OvaRex R 49 EUROPEAN BIOTECHNICA AWARD 49 Alzheimer Disease ICAD 49 #:#-# [007] 49 Allovectin 7 ® 49 ACOSOG Z# 49 #-# Full Text 49 PEARL HF 49 SCD HeFT 49 elacytarabine 49 angiogenesis inhibitor 49 DMAG 48 HYVET 48 LBH# 48 HuMax CD4 48 bortezomib Velcade 48 Panzem R 48 sipuleucel T 48 Experimental Biology EB 48 Sprycel dasatinib 48 clevidipine 48 Xanafide 48 Heart Assn 48 Environ Health Perspect 48 Coronary Revascularization 48 Postgraduate Course 48 See CLINICAL PHARMACOLOGY 48 prospective observational studies 48 FIP Pharmaceutical 48 High Throughput Biology 48 deforolimus 48 Natalizumab 48 Biologic Therapy 48 Chest Physicians CHEST 48 PLK1 SNALP 48 Radiology ECR 48 HIV Pathogenesis 48 gastrointestinal stromal tumors GIST 48 #:#-# [031] 48 ORMD 48 Experimental Hematology 48 Recombinant Human 48 BMC Musculoskeletal Disorders 48 Nephrology ASN Renal 48 Everolimus 48 ISEL 48 Anesthesiologists Annual Meeting 48 Demonstrates Efficacy 48 anti amnesic 48 Medtronic Endeavor stent 48 liposome injection 48 Respiratory Viral Infections 48 DU #b 48 multicentre prospective 48 Heart Failure Therapies 48 Nasdaq PCYC 48 AAPOS 48 Drug Eluting Stents 48 Cellular Immunology 48 CCX#